This site is intended for health professionals only
A British drug company is aiming to develop and distribute new medicines with the help of small and medium-sized Japanese firms.
GlaxoSmithKline is looking to Japan, with many medicines now well established in home markets there and winning approval.
Emerging markets make up 13% of Glaxo group sales and Japan accounts for around 4%. Glaxo’s emerging markets have seen nine-month sales of Â£2.1 billion and year-on-year growth of 19%.
Glaxo would not take a controlling stake in the firms with which it is hoping to work with, said the firm’s Asia-Pacific head Marc Dunoyer.
The Financial Times has reported Mr Dunoyer as claiming the focus of Glaxo will be on the medium-sized segment of Japan.
Mr Dunoyer added: “It’s about reassuring them that we’re not going to take them out, but that we have some complementary areas.”
Copyright Press Association 2010